Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation

Transplant Infectious Disease

Volumn 11, Issue 5, 2009, Pages 438-441

  Aisa, Y ^a   Mori, T ^a   Nakazato, T ^a   Suzuki, S ^a   Suzuki, N ^a   Ikeda, Y ^a   Okamoto, S ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marrow transplantation; Central nervous system; Cerebral hemorrhage; Epstein Barr virus; Post transplant lymphoproliferative disorder

Indexed keywords

B LYMPHOCYTE ANTIGEN; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VIRUS RNA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOPSY; BRAIN HEMORRHAGE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ASSOCIATED POST TRANSPLANTATION LYMPHPROLIFERATIVE DISORDER; FATALITY; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRADIATION; LIVER DISEASE; LUNG DISEASE; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BONE MARROW TRANSPLANTATION; CEREBRAL HEMORRHAGE; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; TRANSPLANTATION CONDITIONING;

EID: 70349659357     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00409.x     Document Type: Article

References (23)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999 94 : 2208 2216.
2. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006 37 : 539 546.
3. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006 108 : 2874 2880.
4. Sundin M, Le Blanc K, Ringdén O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006 91 : 1059 1067.
5. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003 32 : 97 102.
6. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999 23 : 251 258.
7. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996 87 : 3633 3639.
8. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989 321 : 784 789.
9. Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005 129 : 229 239.
10. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007 48 : 256 269.
11. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004 4 : 222 230.
12. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005 37 : 956 957.
13. Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005 5 : 775 780.
14. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006 6 : 2735 2742.
15. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005 37 : 954 955.
16. Phan TG, O'Neill BP, Kurtin PJ. Posttransplant primary CNS lymphoma. Neuro Oncol 2000 2 : 229 238.
17. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004 121 : 246 253.
18. Brennan KC, Lowe LH, Yeaney GA. Pediatric central nervous system posttransplant lymphoproliferative disorder. Am J Neuroradiol 2005 26 : 1695 1697.
19. Nozzoli C, Bartolozzi B, Guidi S, et al. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006 47 : 167 169.
20. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004 103 : 3979 3981.
21. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002 99 : 4364 4369.
22. Gruhn B, Meerbach A, Häfer R, Zell R, Wutzler P, Zintl F. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003 31 : 1023 1025.
23. Hänel M, Fiedler F, Thorns C. Anti-CD20 monoclonal antibody (Rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001 24 : 491 494.